Copyright: ©Author(s) 2026.
World J Clin Oncol. Nov 24, 2026; 17(11): 122944
Published online Nov 24, 2026. doi: 10.5306/wjco.122944
Published online Nov 24, 2026. doi: 10.5306/wjco.122944
Table 2 Long-term outcomes after excluding postoperative early deaths, n (%)/mean ± SD
| Group I (n = 1029) | Group II (n = 157) | Group III (n = 154) | Group IV (n = 210) | P value | |
| Period of follow-up (months) | 57.3 ± 21.9 | 53.9 ± 25.4 | 46.0 ± 24.3 | 41.7 ± 22.7 | < 0.001 |
| Recurrence during the follow-up | 541 (52.6) | 97 (61.8) | 106 (68.8) | 148 (70.5) | < 0.001 |
| Intrahepatic recurrence | 499 (48.5) | 89 (56.7) | 90 (58.4) | 130 (61.9) | 0.001 |
| Extrahepatic recurrence | 18 (1.7) | 3 (1.9) | 4 (2.6) | 5 (2.4) | 0.858 |
| Intra- and extrahepatic recurrence | 24 (2.3) | 5 (3.2) | 12 (7.8) | 13 (6.5) | 0.001 |
| BCLC stage of initial recurrence | 541 (52.6) | 97 (61.8) | 106 (68.8) | 148 (70.5) | < 0.001 |
| BCLC A stage | 345 (33.5) | 55 (35.0) | 53 (34.4) | 61 (29.0) | 0.568 |
| BCLC B stage | 142 (13.8) | 31 (19.7) | 31 (20.1) | 61 (29.0) | < 0.001 |
| BCLC C stage | 54 (5.2) | 11 (7.0) | 22 (14.3) | 26 (12.4) | < 0.001 |
| Mortality during the follow-up | 380 (36.9) | 74 (47.1) | 85 (55.2) | 136 (64.8) | < 0.001 |
| Cancer-specific mortality | 318 (30.9) | 65 (41.4) | 73 (47.4) | 117 (55.7) | < 0.001 |
| Non-cancer-specific mortality | 62 (6.0) | 9 (5.7) | 12 (7.8) | 19 (9.0) | 0.370 |
| Overall survival | 107.7 (-) | 76.4 (57.8-95.0) | 51.0 (33.6-68.5) | 43.0 (33.8-52.2) | < 0.001 |
| 1-year OS rate (%) | 96.1 | 91.7 | 91.6 | 88.1 | |
| 3-year OS rate (%) | 80.3 | 73.2 | 63.0 | 71.0 | |
| 5-year OS rate (%) | 68.2 | 59.4 | 47.8 | 36.7 | |
| Recurrence free survival | 48.8 (41.7-55.9) | 38.4 (21.9-55.0) | 19.2 (12.2-26.2) | 13.6 (8.9-18.3) | < 0.001 |
| 1-year RFS rate (%) | 75.9 | 72.0 | 59.7 | 53.3 | |
| 3-year RFS rate (%) | 56.0 | 50.3 | 35.7 | 32.9 | |
| 5-year RFS rate (%) | 45.6 | 39.1 | 29.7 | 24.2 |
- Citation: Shen HX, Song YS, Wang HF, Chen C, Song JK, Sun CG, Miao SZ, Chen XG, Bai SL, Zhao YF, Wang K. Comprehensive prognostic value of prealbumin and albumin in hepatocellular carcinoma resection: Insights from a Chinese multicenter cohort. World J Clin Oncol 2026; 17(11): 122944
- URL: https://www.wjgnet.com/2218-4333/full/v17/i11/122944.htm
- DOI: https://dx.doi.org/10.5306/wjco.122944